Kidney Transplant Endpoints Strive For Acceptance At FDA Workshop
Executive Summary
Traditional endpoints are becoming increasingly difficult to use successfully in clinical trials because the standard of care has become highly effective.
You may also be interested in...
Chronic Kidney Disease Trials Could Gain New Surrogate Endpoints
FDA is considering the use of 30% and 40% reductions in glomerular filtration rate as surrogate endpoints for the development of kidney failure in clinical trials; the current standard is 50%.
Zortress Approval Delay Caused By Novartis Attempts To Avoid Controlled Trial Of Dosing Regimen
Sponsors cannot cut corners in developing clinical data to support a revised dosing scheme, even when a drug’s efficacy has already been shown, Novartis learned while shepherding its kidney transplant agent Zortress (everolimus) through the FDA approval process.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.